BeOne Medicines (ONC) Depreciation and Depletion (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Depreciation and Depletion data on file, last reported at $39.4 million in Q1 2026.

• Quarterly Depreciation and Depletion rose 24.58% year-over-year to $39.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $139.4 million (down 20.1% YoY) and the FY2025 annual result came in at $131.6 million, down 21.16% from the prior year.
• Depreciation and Depletion improved to $39.4 million in Q1 2026 per ONC's latest filing, from $34.4 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $70.0 million in Q3 2024 and bottomed at $14.5 million in Q2 2022.
• The 5-year median for Depreciation and Depletion is $23.8 million (2024), against an average of $28.3 million.
• The widest annual swing landed in 2024, when Depreciation and Depletion jumped 263.93%; it then plunged 48.98% in 2025.
• Tracing ONC's Depreciation and Depletion over 5 years: stood at $17.0 million in 2022, then advanced by 22.38% to $20.9 million in 2023, then jumped by 135.1% to $49.0 million in 2024, then dropped by 29.83% to $34.4 million in 2025, then gained by 14.43% to $39.4 million in 2026.
• Per Business Quant, the three latest ONC Depreciation and Depletion figures stand at $39.4 million (Q1 2026), $34.4 million (Q4 2025), and $35.7 million (Q3 2025).

Peer Comparison